Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions

Pavelić, Krešimir; Dedivitis, Rogério Aparecido; Kapitanović, Sanja; Čačev, Tamara; Guirado, Cristiano Rosa; Đanić, Davorin; Radošević, Senka; Brkić, Kornelije; Pegan, Boris; Križanac, Šimun; Kusić, Zvonko; Spaventi, Šime; Bura, Miljenko

doi:10.1016/j.mrfmmm.2006.01.021

Cited by 18 publications

(18 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Up-regulation of FHIT, p16 and PPAR-γ have also been shown to result in cell-cycle arrest and apoptosis. 13 -15 Previous studies have demonstrated low to absent p16 or FHIT immunoreactivity in thyroid carcinomas 4,16 and, in the present study, their expression in thyroid carcinomas was found to be low. Conversely their expression has been found to be uniformly high in other benign endocrine tumours.…”

Section: Discussionsupporting

confidence: 46%

Comparative Analysis of Protein Expression in Differentiated Thyroid Tumours: A Multicentre Study

Liang

Luo

et al. 2009

J Int Med Res

View full text Add to dashboard Cite

This study compared clinical features and protein expression profiles in differentiated thyroid tumours to identify protein markers with the potential for indicating malignancy status. Tissue microarrays were constructed using 119 thyroid tumour samples (45 papillary carcinomas, 26 follicular carcinomas, 48 adenomas). Generally, there was overexpression of proliferating cell nuclear antigen (PCNA), p53, matrix metalloproteinase (MMP)-7, Hector Battifora mesothelial-1 (HBME-1), MMP-2, pituitary tumour-transforming gene (PTTG) and human telomerase reverse transcriptase (hTERT) in malignant thyroid carcinomas, and overexpression of fragile histidine triad (FHIT), p16 and Ecadherin in thyroid adenomas. Multiple factor binary logistic regression analysis indicated that MMP-2, HBME-1, p16 and FHIT were independently related to differentiated thyroid tumours. Receiveroperating characteristics for these four factors showed HBME-1 as best for diagnostic accuracy. Sensitivity and specificity were enhanced using an HBME-1 and p16 cluster. HBME-1 expression was not significantly different for papillary and follicular carcinomas, whereas p16 expression was significantly specific.

show abstract

Section: Discussionsupporting

confidence: 46%

Comparative Analysis of Protein Expression in Differentiated Thyroid Tumours: A Multicentre Study

Liang

Luo

et al. 2009

J Int Med Res

View full text Add to dashboard Cite

show abstract

“…They have also determined that in metastatic lymph node carcinoma, FHIT expression has no relationship to primary tumor expression [26]. Pavelic et al [27] have stated that in malignant thyroid gland lesions, the decreasing FHIT expression and apoptosis can be related to malignance and be used as a prognostic factor.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of Fhit and Wwox Proteins Expression in Laryngeal Cancer

G¹

2013

Otolaryngology

View full text Add to dashboard Cite

“…This alteration is present in virtually all familial cases and up to 50% of the sporadic cases (table 1) (3). A recent paper reported a high prevalence of TP53 mutations in MTC (11).…”

Section: Massimo Santoro Alfredo Fuscomentioning

confidence: 97%

“…hemiz del (60%) 9 various (67-88%) 2 various (50%) 11 Tumor type Gene alteration activity by binding to the catalytic domain, often the ATP binding pocket, of the kinase. The paradigm of imatinib (Gleevec) for BCR-ABL-positive chronic myelogenous leukaemia (CML) and for stem cell growth factor receptor (c-KIT)-positive gastrointestinal stromal tumours (GIST) and of EGFR inhibitors in EGFR-mutation positive non-small cell lung carcinomas (NSCLC) has exemplified the power of this approach (12).…”

Section: Novel Molecular Targets For the Treatment Of Thyroid Carcinomamentioning

confidence: 99%

New drugs in thyroid cancer

Santoro

2007

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

This review is focused on "new drugs" that might be developed for thyroid cancer treatment. Thyroid cancer is frequently associated to the activation of specific protein (RET, BRAF) and lipid [PI(3)K] kinases. There is good evidence that these genetic lesions are causative events in thyroid cancer initiation or progression. Therefore, novel compounds able to target these kinases might be useful for thyroid cancer treatment. The power of this approach is witnessed by the examples of BCR-ABL, c-KIT and EGFR inhibitors in the treatment of chronic myelogenous leukemia (CML), gastro-intestinal stromal tumors (GIST) and non-small cell lung carcinoma (NSCLC).

show abstract

Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions

Cited by 18 publications

References 44 publications

Comparative Analysis of Protein Expression in Differentiated Thyroid Tumours: A Multicentre Study

Comparative Analysis of Protein Expression in Differentiated Thyroid Tumours: A Multicentre Study

Prognostic Significance of Fhit and Wwox Proteins Expression in Laryngeal Cancer

New drugs in thyroid cancer

Contact Info

Product

Resources

About